Monoclonal antibodies: magic bullets with a hefty price tag

被引：80

作者：

Shaughnessy, Allen F. ^{[1
]}

机构：

[1] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

BRITISH MEDICAL JOURNAL | 2012年 / 345卷

关键词：

CONTROLLED PHASE-3 TRIAL; MULTIPLE-SCLEROSIS; ALEMTUZUMAB;

D O I：

10.1136/bmj.e8346

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 9 条

[1]

[Anonymous], 2012, LANCET, V380, P1792

[2]

Bourgoin AF, WHAT YOU NEED KNOW F

[3] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].

Cohen, Jeffrey A. ;

Coles, Alasdair J. ;

Arnold, Douglas L. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Fisher, Elizabeth ;

Brinar, Vesna V. ;

Giovannoni, Gavin ;

Stojanovic, Miroslav ;

Ertik, Bella I. ;

Lake, Stephen L. ;

Margolin, David H. ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1819-1828

[4] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial [J].

Coles, Alasdair J. ;

Twyman, Cary L. ;

Arnold, Douglas L. ;

Cohen, Jeffrey A. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Miller, Tamara ;

Fisher, Elizabeth ;

Sandbrink, Rupert ;

Lake, Stephen L. ;

Margolin, David H. ;

Oyuela, Pedro ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1829-1839

[5]

Fanneau de La Horie GC, MAKING BIOL DRUGS MO

[6]

Herper M, WORLDS MOST EXPENSIV

[7] Industrialization of mAb production technology The bioprocessing industry at a crossroads [J].

Kelley, Brian .

MABS, 2009, 1 (05) :443-452

[8]

Staton T, SANOFI PULLS CAMPATH

[9]

U.S. Food and Drug Administration, BIOS

← 1 →